TRVN
- Trevena, Inc.
()
Overview
Company Summary
Trevena, Inc. is a biopharmaceutical company that focuses on the discovery and development of innovative therapies for serious medical conditions. Founded in 2007 and headquartered in Chesterbrook, Pennsylvania, Trevena is dedicated to bringing new treatments to patients in need.
The core focus of Trevena's research and development efforts lies in the field of G protein-coupled receptors (GPCRs). GPCRs are a large group of proteins located on the surface of cells. They play a vital role in various physiological processes, acting as key targets for drug intervention. By leveraging its expertise in GPCR biology and medicinal chemistry, Trevena aims to develop new medications that modulate these receptors to treat a wide range of diseases and disorders.
Trevena has built a robust pipeline of drug candidates, with an emphasis on areas such as acute heart failure, migraine, moderate-to-severe pain, and postoperative pain. They employ a unique approach to drug development, utilizing their proprietary research platform and advanced methods of identifying and targeting GPCRs.
One of the notable drug candidates in Trevena's pipeline is Oliceridine (brand name: Olinvyk), which is an intravenous opioid designed to manage moderate-to-severe acute pain. Olinvyk has been approved by the U.S. Food and Drug Administration (FDA) and provides an alternative to currently available opioids with potential advantages in terms of efficacy, safety, and reduced risk of overdose.
Overall, Trevena, Inc. is dedicated to advancing the field of GPCR-based drug discovery and has positioned itself as a leader in developing innovative therapeutics for challenging medical conditions, with the ultimate goal of improving patient outcomes and quality of life.